FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282937503> ?p ?o ?g. }

• W4282937503 endingPage "716" @default.
• W4282937503 startingPage "716" @default.
• W4282937503 abstract "Abstract Herein, we report silibinin (a natural flavonolignan from milk thistle seeds) efficacy against basal cell carcinoma (BCC), the major non-melanoma skin cancer. To determine the preventive/therapeutic activity of silibinin on the progression of UVB-induced microscopic BCC lesions to more advanced BCC, both male and female 8 weeks old Ptch1+/- mice were irradiated with 240 mJ/cm2 UVB dose 3 times/week (M, W, F) for 26 weeks, and thereafter, UVB irradiation was stopped. At this point (after initial UVB exposure for 26 weeks was stopped), these Ptch1+/- mice were randomized into 3 groups: Baseline group (mice euthanized for baseline data); Vehicle group: mice treated topically with acetone for 20 more weeks, and Silibinin group: mice treated topically with silibinin (9 mg in 200 µL acetone), once a day for five days/week for 20 more weeks i.e., till 54 weeks of mice age. Assessment of BCC and non-BCC lesion pathology was performed following β-galactosidase and H&E based histopathological analysis. Results indicated that compared to BCC-associated pathologies observed at baseline, acetone exposure for another 20 weeks resulted in a significant increase in the number (~2 folds, P&lt;0.001) and area (~3.4 folds, P&lt;0.001) covered by BCC lesions. There was also a significant increase in epidermal dysplasia, fibrosarcoma, and squamous cell carcinoma incidence. Notably, topical application of silibinin during this phase significantly decreased BCC numbers as well as area covered by BCC lesions by ~76% (P&lt;0.001) and ~88% (P&lt;0.001), respectively. This protective effect of silibinin was associated with decreased proliferation of basal cells and decreased expression of Hh signaling molecules (Smo and Gli1). To further delineate the changes associated with silibinin’ s protective effect at the transcriptomic level, RNA sequencing studies were performed in skin samples from all three groups as well as non-UVB exposed control mice. Clustering of mRNA profile by sparse Partial Least Squares - Discriminant Analysis (sPLS-DA) showed that UVB exposed tissues (not treated with silibinin) were significantly different from non-UVB controls; most notably, silibinin treatment (after UVB exposure) reversed this phenomenon and the transcriptomic profile of silibinin group was almost similar to non-UVB controls. This indicated that topical silibinin was not only able to protect against progression to advanced BCC but had the potential to even normalize the aberrant gene expression driving BCC formation. In addition, Gene ontology enrichment analysis as well as Pathway enrichment analysis of differentially expressed genes showed silibinin-associated enrichment in the calcium and CX3CR1-mediated signaling pathway, and TGF-β-mediated regulation of the extracellular matrix. Taken together, these results highlight the potential of silibinin to be an effective preventive and/or therapeutic modality against BCC growth and progression. Citation Format: Komal Raina, Sandeep Paudel, Neha Mishra, Sushil Kumar, David J. Orlicky, Zhiying You, Rama Kant, Chapla Agarwal, Rajesh Agarwal. Silibinin: A novel potential therapeutic agent against UVB-induced basal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 716." @default.
• W4282937503 created "2022-06-16" @default.
• W4282937503 creator A5027734680 @default.
• W4282937503 creator A5032064580 @default.
• W4282937503 creator A5035937118 @default.
• W4282937503 creator A5042554532 @default.
• W4282937503 creator A5048444823 @default.
• W4282937503 creator A5052783130 @default.
• W4282937503 creator A5060497987 @default.
• W4282937503 creator A5070929898 @default.
• W4282937503 creator A5071219911 @default.
• W4282937503 date "2022-06-15" @default.
• W4282937503 modified "2023-10-07" @default.
• W4282937503 title "Abstract 716: Silibinin: A novel potential therapeutic agent against UVB-induced basal cell carcinoma" @default.
• W4282937503 doi "https://doi.org/10.1158/1538-7445.am2022-716" @default.
• W4282937503 hasPublicationYear "2022" @default.
• W4282937503 type Work @default.
• W4282937503 citedByCount "1" @default.
• W4282937503 countsByYear W42829375032023 @default.
• W4282937503 crossrefType "journal-article" @default.
• W4282937503 hasAuthorship W4282937503A5027734680 @default.
• W4282937503 hasAuthorship W4282937503A5032064580 @default.
• W4282937503 hasAuthorship W4282937503A5035937118 @default.
• W4282937503 hasAuthorship W4282937503A5042554532 @default.
• W4282937503 hasAuthorship W4282937503A5048444823 @default.
• W4282937503 hasAuthorship W4282937503A5052783130 @default.
• W4282937503 hasAuthorship W4282937503A5060497987 @default.
• W4282937503 hasAuthorship W4282937503A5070929898 @default.
• W4282937503 hasAuthorship W4282937503A5071219911 @default.
• W4282937503 hasConcept C121608353 @default.
• W4282937503 hasConcept C126322002 @default.
• W4282937503 hasConcept C142724271 @default.
• W4282937503 hasConcept C2777130413 @default.
• W4282937503 hasConcept C2777789703 @default.
• W4282937503 hasConcept C2778804307 @default.
• W4282937503 hasConcept C3019992690 @default.
• W4282937503 hasConcept C71924100 @default.
• W4282937503 hasConcept C98274493 @default.
• W4282937503 hasConceptScore W4282937503C121608353 @default.
• W4282937503 hasConceptScore W4282937503C126322002 @default.
• W4282937503 hasConceptScore W4282937503C142724271 @default.
• W4282937503 hasConceptScore W4282937503C2777130413 @default.
• W4282937503 hasConceptScore W4282937503C2777789703 @default.
• W4282937503 hasConceptScore W4282937503C2778804307 @default.
• W4282937503 hasConceptScore W4282937503C3019992690 @default.
• W4282937503 hasConceptScore W4282937503C71924100 @default.
• W4282937503 hasConceptScore W4282937503C98274493 @default.
• W4282937503 hasIssue "12_Supplement" @default.
• W4282937503 hasLocation W42829375031 @default.
• W4282937503 hasOpenAccess W4282937503 @default.
• W4282937503 hasPrimaryLocation W42829375031 @default.
• W4282937503 hasRelatedWork W10191283 @default.
• W4282937503 hasRelatedWork W2017577682 @default.
• W4282937503 hasRelatedWork W2029706239 @default.
• W4282937503 hasRelatedWork W2051704735 @default.
• W4282937503 hasRelatedWork W2062159889 @default.
• W4282937503 hasRelatedWork W2116661571 @default.
• W4282937503 hasRelatedWork W2140085404 @default.
• W4282937503 hasRelatedWork W3093398530 @default.
• W4282937503 hasRelatedWork W4361252764 @default.
• W4282937503 hasRelatedWork W4384787935 @default.
• W4282937503 hasVolume "82" @default.
• W4282937503 isParatext "false" @default.
• W4282937503 isRetracted "false" @default.
• W4282937503 workType "article" @default.